Cognition Therapeutics In... (CGTX)
| Bid | 0.44 |
| Market Cap | 27.58M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -33.97M |
| EPS (ttm) | -0.86 |
| PE Ratio (ttm) | -0.52 |
| Forward PE | -0.44 |
| Analyst | Buy |
| Ask | 0.45 |
| Volume | 335,235 |
| Avg. Volume (20D) | 1,321,891 |
| Open | 0.42 |
| Previous Close | 0.43 |
| Day's Range | 0.41 - 0.45 |
| 52-Week Range | 0.30 - 2.95 |
| Beta | 1.00 |
About CGTX
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinica...
Analyst Forecast
According to 5 analyst ratings, the average rating for CGTX stock is "Buy." The 12-month stock price forecast is $6.5, which is an increase of 1360.35% from the latest price.
Stock Forecasts
1 month ago · seekingalpha.com
Cognition Therapeutics, Inc (CGTX) Q4 2024 Earnings Call TranscriptCognition Therapeutics, Inc (NASDAQ:CGTX ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Mike Moyer - LifeSci Advisors Lisa Ricciardi - Chief Executive Officer John Do...